Abstract
The acquisition of metastatic features in tumor cells encompasses genetic and non-genetic adaptation, including reprogramming of cellular metabolism. Here we show that loss of UFMylation reroutes glucose metabolism, promotes invasive capacity and supports prostate cancer metastasis. Through transcriptome-based bioinformatics analysis, we identified a reduction in the ubiquitin-like modifier UFM1 and its ligase UFL1 in metastatic prostate cancer. We demonstrate that loss of UFMylation results in enhanced cancer cell dissemination and a switch from cellular proliferation to invasion. Using biotin-based proteomics, we identified phosphofructokinase (PFKAP) as an unprecedented UFMylation substrate. Consistent with UFMylation playing a role in the regulation of phosphofructokinase activity, loss of UFMylation reduced glucose metabolism in favour of hexosamine biosynthesis, which resulted in elevated glycosylation of proteins relevant for cell invasion. These results reveal a role for UFMylation in the regulation of phosphofructokinase and glucose metabolism to support prostate cancer metastasis.
Funding Information
  • EMBO (Scientific Exchange Grant (#10477))
  • Basque Department of Industry, Tourism and Trade
  • Fundación CRIS contra el cancer (PR_EX_2021-22)
  • Fundación CRIS contra el cancer (PR_TPD_2020-19)
  • Severo Ochoa Excellence Accreditation (CEX2021-001136-S)
  • iDIFFER network of Excellence (RED2022-134792-T)
  • AstraZeneca Foundation (award to young investigators 2023)
  • Leonardo Grant for Scientific Research and Cultural Creation (Beca Leonardo LEO23-2-10984-BBM-TRA-261)
  • CIBERONC (CIBERONC)
  • Marie Sklodowska-Curie Actions Individual Fellowship (MSCA-IF-2018-839896)
  • FWO projects (FWO Projects)
  • Fonds Baillet Latour, KU Leuven (Fonds Baillet Latour, KU Leuven)
  • MIT Center for Precision Cancer Medicine (MIT Center for Precision Cancer Medicine)
  • NCI (R35CA242379)
  • NCI (R01CA259253)
  • NCI (P30CA1405141)

This publication has 49 references indexed in Scilit: